The Clinical Trials Market 2006~Published by Visiongain, Febraury 2006
The global clinical trials industry is currently worth an estimated $10 billion and has the potential for considerable growth in the future. Global revenues from clinical trials have increased by almost 15% in the last year and the industry is prepared for an extended period of healthy growth. Concern over safety and an extremely competitive pharmaceutical market has driven demand for large clinical trials but will also radically change how clinical trials are regulated and designed. This report discusses the dynamic future of the clinical trials market.
~
Untitled DocumentPublished by Visiongain, Febraury 2006
The global clinical trials industry is currently worth an estimated $10 billion and has the potential for considerable growth in the future. Global revenues from clinical trials have increased by almost 15% in the last year and the industry is prepared for an extended period of healthy growth. Concern over safety and an extremely competitive pharmaceutical market has driven demand for large clinical trials but will also radically change how clinical trials are regulated and designed. This report discusses the dynamic future of the clinical trials market.
Will the current trend to outsource clinical trials to Asia be successful? How will the emerging discipline of pharmacogenomics affect drug development in the future? What kind of restrictions will authorities such as the FDA and the EMEA impose in the future? Read visiongain's brand new report to find out.
The report investigates these key issues:
* How changes to the attitudes of regulatory authorities will effect the nature of clinical trials
* The role of public education for improved patient recruitment?
* An assessment of clinical trials in developing countries, including SWOT analysis
* A review of clinical trials in India and China
* A financial forecast for the global clinical trials market 2005-2011
* A geographic breakdown of the clinical trials market, including US, Europe, and Asia (including Japan) 2005-2011
* The growth of contract research organisations in clinical trials: including company profiles of the top 10 CROs
* How can new technology such as electronic data capture (EDC) and pharmacogenomics be successfully integrated into clinical trials?
Why you should buy this report
The world pharmaceutical market looks set to undergo a major transformation following the ensuing loss of present blockbuster drugs. Efficient clinical trials are going to be vital for success and all pharmaceutical companies and CROs need to remain responsive to future changes in this fast moving market. This report gives invaluable insight into what visiongain believes are the major challenges for clinical trials in the years to come.
“The Clinical Trials Market 2006” includes over 100 pages of in-depth analysis and opinion, with data presented in over 60 tables and figures.
Tabel of Contents ~The Clinical Trials Market 2006 (Single user License PDF)|950|The Clinical Trials Market 2006 (Department License PDF)|951|The Clinical Trials Market 2006 (Company wide license PDF)|952|~1838~3029~~
Tissue Microarrays~
Published by Select Biosciences, May 2004
The report provides in-depth information on the market and size segmented by technology and application. In addition to a detailed market model, Tissue Microarrays : Market Assessment and Opportunities evaluates the strengths and weaknesses of each of the TMA vendors, and assesses both opportunities and threats facing their products & services. The companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward are identified.
~Published by Select Biosciences, May 2004
The report provides in-depth information on the market and size segmented by technology and application. In addition to a detailed market model, Tissue Microarrays : Market Assessment and Opportunities evaluates the strengths and weaknesses of each of the TMA vendors, and assesses both opportunities and threats facing their products & services. The companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward are identified.
View Full Table of Contents~Tissue Microarrays%3A Full Report - Single user print version|48|Tissue Microarrays%3A Full Report - PDF site License +1 print copy|619|~1838~1839~~